Claims for Patent: 11,524,951

Summary for Patent: 11,524,951

Title:	2-(2,4,5-substituted-anilino)pyrimidine compounds
Abstract:	The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
Inventor(s):	Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew WARD, Heather Marie REDFEARN, Vasantha Krishna KADAMBAR, Chandrasekhara Reddy Chintakuntla, Andiappan Murugan, Claudio Edmundo Chuaqui
Assignee:	AstraZeneca UK Ltd , AstraZeneca AB
Application Number:	US17/096,167
Patent Claims:	1. A compound of Formula (I): wherein: G is selected from 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl and pyrazolo[1,5-a]pyridin-3-yl; R1 is selected from hydrogen, fluoro, chloro, methyl and cyano; R2 is selected from methoxy and methyl; and R3 is selected from (3R)-3-(dimethylamino)pyrrolidin-1-yl, (3S)-3-(dimethyl-amino)pyrrolidin-1-yl, 3-(dimethylamino)azetidin-1-yl, [2-(dimethylamino)ethyl]-(methyl)amino, [2-(methylamino)ethyl](methyl)amino, 5-methyl-2,5-diazaspiro[3.4]oct-2-yl, (3aR,6aR)-5-methylhexa-hydro-pyrrolo[3,4-b]pyrrol-1(2H)-yl, 1-methyl-1,2,3,6-tetrahydropyridin-4-yl, 4-methylpiperazin-1-yl, 4-[2-(dimethylamino)-2-oxoethyl]piperazin-1-yl, methyl[2-(4-methylpiperazin-1-yl)ethyl]amino, methyl[2-(morpholin-4-yl)ethyl]amino-and 4-[(2S)-2-aminopropanoyl]piperazin-1-yl; or a pharmaceutically acceptable salt thereof. 2. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein G is selected from 1H-indol-3-yl, 1-methyl-1H-indol-3-yl and pyrazolo[1,5-a]pyridin-3-yl. 3. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein R1 is hydrogen. 4. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein R2 is methoxy. 5. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein G is 1-methyl-1H-indol-3-yl. 6. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein R3 is [2-(dimethylamino)ethyl]-(methyl)amino. 7. A pharmaceutical composition, which comprises the compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, in association with a pharmaceutically-acceptable diluent or carrier. 8. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein R3 is [2-(methylamino)ethyl](methyl)amino.